Direct
NAV (25-Jul-24)
Returns (Since Inception)
Fund Size
₹15 Cr
Expense Ratio
0.22%
ISIN
INF247L01BB1
Minimum SIP
-
Exit Load
-
Inception Date
29 Jul 2022
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+46.71%
+45.90% (Cat Avg.)
Since Inception
+31.78%
— (Cat Avg.)
Equity | ₹14.95 Cr | 99.67% |
Others | ₹0.05 Cr | 0.33% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹2.28 Cr | 15.21% |
Cipla Ltd | Equity | ₹1.1 Cr | 7.30% |
Dr Reddy's Laboratories Ltd | Equity | ₹1.08 Cr | 7.22% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹0.97 Cr | 6.44% |
Apollo Hospitals Enterprise Ltd | Equity | ₹0.86 Cr | 5.76% |
Divi's Laboratories Ltd | Equity | ₹0.81 Cr | 5.42% |
Lupin Ltd | Equity | ₹0.54 Cr | 3.62% |
Aurobindo Pharma Ltd | Equity | ₹0.47 Cr | 3.14% |
Zydus Lifesciences Ltd | Equity | ₹0.38 Cr | 2.50% |
Torrent Pharmaceuticals Ltd | Equity | ₹0.35 Cr | 2.36% |
Alkem Laboratories Ltd | Equity | ₹0.35 Cr | 2.32% |
Fortis Healthcare Ltd | Equity | ₹0.34 Cr | 2.29% |
Mankind Pharma Ltd | Equity | ₹0.3 Cr | 1.97% |
Glenmark Pharmaceuticals Ltd | Equity | ₹0.26 Cr | 1.70% |
Laurus Labs Ltd | Equity | ₹0.23 Cr | 1.55% |
Biocon Ltd | Equity | ₹0.22 Cr | 1.44% |
Ipca Laboratories Ltd | Equity | ₹0.21 Cr | 1.41% |
Abbott India Ltd | Equity | ₹0.2 Cr | 1.36% |
Global Health Ltd | Equity | ₹0.18 Cr | 1.20% |
Syngene International Ltd | Equity | ₹0.18 Cr | 1.19% |
Gland Pharma Ltd | Equity | ₹0.18 Cr | 1.17% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹0.17 Cr | 1.16% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹0.15 Cr | 1.00% |
Natco Pharma Ltd | Equity | ₹0.14 Cr | 0.97% |
Suven Pharmaceuticals Ltd | Equity | ₹0.14 Cr | 0.95% |
Dr. Lal PathLabs Ltd | Equity | ₹0.14 Cr | 0.95% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹0.14 Cr | 0.94% |
Piramal Pharma Ltd | Equity | ₹0.13 Cr | 0.88% |
Ajanta Pharma Ltd | Equity | ₹0.13 Cr | 0.88% |
Concord Biotech Ltd | Equity | ₹0.13 Cr | 0.84% |
Poly Medicure Ltd | Equity | ₹0.12 Cr | 0.81% |
Narayana Hrudayalaya Ltd | Equity | ₹0.11 Cr | 0.75% |
Pfizer Ltd | Equity | ₹0.1 Cr | 0.67% |
Granules India Ltd | Equity | ₹0.09 Cr | 0.62% |
Strides Pharma Science Ltd | Equity | ₹0.09 Cr | 0.60% |
Neuland Laboratories Limited | Equity | ₹0.09 Cr | 0.59% |
Rainbow Childrens Medicare Ltd | Equity | ₹0.09 Cr | 0.59% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹0.08 Cr | 0.51% |
Jubilant Pharmova Ltd | Equity | ₹0.08 Cr | 0.51% |
Metropolis Healthcare Ltd | Equity | ₹0.07 Cr | 0.47% |
Wockhardt Ltd | Equity | ₹0.07 Cr | 0.47% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹0.07 Cr | 0.45% |
Jupiter Life Line Hospitals Ltd | Equity | ₹0.07 Cr | 0.45% |
Alembic Pharmaceuticals Ltd | Equity | ₹0.07 Cr | 0.45% |
Procter & Gamble Health Ltd | Equity | ₹0.06 Cr | 0.37% |
Marksans Pharma Ltd | Equity | ₹0.06 Cr | 0.37% |
AstraZeneca Pharma India Ltd | Equity | ₹0.05 Cr | 0.36% |
Net Receivables / (Payables) | Cash - Collateral | ₹0.05 Cr | 0.33% |
Vijaya Diagnostic Centre Ltd | Equity | ₹0.05 Cr | 0.33% |
Caplin Point Laboratories Ltd | Equity | ₹0.04 Cr | 0.28% |
Aarti Pharmalabs Ltd | Equity | ₹0.04 Cr | 0.28% |
Shilpa Medicare Ltd | Equity | ₹0.04 Cr | 0.26% |
Ami Organics Ltd | Equity | ₹0.04 Cr | 0.24% |
Sun Pharma Advanced Research Co Ltd | Equity | ₹0.03 Cr | 0.22% |
FDC Ltd | Equity | ₹0.03 Cr | 0.21% |
Kovai Medical Center & Hospital Ltd | Equity | ₹0.03 Cr | 0.18% |
Advanced Enzyme Technologies Ltd | Equity | ₹0.03 Cr | 0.17% |
Glenmark Life Sciences Ltd | Equity | ₹0.03 Cr | 0.17% |
Morepen Laboratories Ltd | Equity | ₹0.02 Cr | 0.16% |
Aarti Drugs Ltd | Equity | ₹0.02 Cr | 0.15% |
HealthCare Global Enterprises Ltd | Equity | ₹0.02 Cr | 0.14% |
Sequent Scientific Ltd | Equity | ₹0.02 Cr | 0.13% |
Hikal Ltd | Equity | ₹0.02 Cr | 0.12% |
Indoco Remedies Ltd | Equity | ₹0.02 Cr | 0.11% |
Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹0.02 Cr | 0.11% |
Dishman Carbogen Amics Ltd | Equity | ₹0.02 Cr | 0.11% |
Krsnaa Diagnostics Ltd | Equity | ₹0.02 Cr | 0.10% |
Unichem Laboratories Ltd | Equity | ₹0.02 Cr | 0.10% |
Indraprastha Medical Corp Ltd | Equity | ₹0.01 Cr | 0.10% |
Supriya Lifescience Ltd | Equity | ₹0.01 Cr | 0.09% |
Gujarat Themis Biosyn Ltd | Equity | ₹0.01 Cr | 0.09% |
Blue Jet Healthcare Ltd | Equity | ₹0.01 Cr | 0.09% |
Thyrocare Technologies Ltd | Equity | ₹0.01 Cr | 0.09% |
Solara Active Pharma Sciences Ltd Ordinary Shares | Equity | ₹0.01 Cr | 0.09% |
Sigachi Industries Ltd | Equity | ₹0.01 Cr | 0.09% |
Hester Biosciences Ltd | Equity | ₹0.01 Cr | 0.09% |
IOL Chemicals And Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.09% |
Gufic Biosciences Ltd | Equity | ₹0.01 Cr | 0.08% |
Tarsons Products Ltd | Equity | ₹0.01 Cr | 0.07% |
Novartis India Ltd | Equity | ₹0.01 Cr | 0.07% |
Innova Captab Ltd | Equity | ₹0.01 Cr | 0.07% |
Shalby Ltd | Equity | ₹0.01 Cr | 0.07% |
RPG Life Sciences Ltd | Equity | ₹0.01 Cr | 0.07% |
Kopran Ltd | Equity | ₹0.01 Cr | 0.06% |
SMS Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.06% |
Suven Life Sciences Ltd | Equity | ₹0.01 Cr | 0.06% |
Bliss GVS Pharma Ltd | Equity | ₹0.01 Cr | 0.06% |
Themis Medicare Ltd | Equity | ₹0.01 Cr | 0.06% |
Lincoln Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.05% |
Syncom Formulation (India) Ltd | Equity | ₹0.01 Cr | 0.05% |
Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹0.01 Cr | 0.05% |
NGL Fine-Chem Ltd | Equity | ₹0.01 Cr | 0.04% |
Vimta Labs Ltd | Equity | ₹0 Cr | 0.03% |
KMC Speciality Hospitals (India) Ltd | Equity | ₹0 Cr | 0.03% |
Bajaj Healthcare Ltd | Equity | ₹0 Cr | 0.03% |
Jagsonpal Pharmaceuticals Ltd | Equity | ₹0 Cr | 0.02% |
Medicamen Biotech Ltd | Equity | ₹0 Cr | 0.02% |
Sastasundar Ventures Ltd | Equity | ₹0 Cr | 0.02% |
Panacea Biotec Ltd | Equity | ₹0 Cr | 0.01% |
Large Cap Stocks
45.25%
Mid Cap Stocks
31.23%
Small Cap Stocks
22.60%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹14.8 Cr | 98.67% |
Basic Materials | ₹0.06 Cr | 0.41% |
Standard Deviation
This fund
--
Cat. avg.
14.65%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.55
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
0.92
Higher the better
Since July 2022
Since November 2022
ISIN | INF247L01BB1 | Expense Ratio | 0.22% | Exit Load | - | Fund Size | ₹15 Cr | Age | 29 Jul 2022 | Lumpsum Minimum | ₹500 | Fund Status | Open Ended Investment Company | Benchmark | BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Flat 15% tax on realised gains (STCG - short term capital gains)
10% tax on realised gains above Rs. 1 lakh per financial year (LTCG - long term capital gains)
Note: Mutual funds are subject to capital gains taxation with surcharge and cess, based on prevailing income tax rules and investor income. Taxation applies to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹15.00 Cr | 46.7% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹713.42 Cr | 48.3% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹713.42 Cr | 46.3% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹29.73 Cr | 45.2% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹173.47 Cr | 45.0% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹173.47 Cr | 42.3% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2312.48 Cr | 45.8% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹2312.48 Cr | 43.7% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹638.88 Cr | 47.4% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹17.23 Cr | 44.1% |
Total AUM
₹57,915 Cr
Address
Motilal Oswal Tower, Mumbai, 400 025
Your principal amount will be at Very High Risk